Popular Combination Asthma Inhalers Found Safe for Children

Popular Combination Asthma Inhalers Found Safe for Children
Little boy using Asthma inhaler for breathing on white background
Last updated:

Concerns over popular combination inhalers for children with asthma that it may lead to an increased risk of asthma-related hospitalization are unwarranted, based on the results of a new study.

Advair Diskus combines a long-acting beta agonist (LABA), salmeterol, with a corticosteroid, fluticasone propionate, to reduce asthma symptoms by opening airways and reducing inflammation. Symbicort, which contains formoterol (LABA) and budesonide (corticosteroid), does the same thing.

In a 2008 analysis, the FDA found studies that seemed to indicate a connection between LABAs and asthma-related deaths in adults and hospitalizations in children. As a result, a “black box” warning –- the most stringent the FDA can require –- was placed on the label of asthma medications containing a LABA.

In one of the new trials, researchers enrolled 6,200 children with asthma between the ages of 4 and 11. They were then randomly given an inhaler that contained either salmeterol and fluticasone (the medications in Advair Diskus), or fluticasone alone.

A total of 27 children in the Advair group had a serious asthma-related event that required hospitalization, while 21 in the steroid-only group did, the researchers reported in the New England Journal of Medicine. The results indicated the risk of hospitalization was not significantly different between the 2 groups. No deaths were reported.

The Symbicort trial, also published in the New England Journal of Medicine,  was designed the same way. This study enrolled 11,693 people aged 12 and older with asthma. A total of 43 patients that received Symbicort had a serious asthma-related event compared to 40 patients who only received budesonide. Again, the difference was not statistically significant.

The trials were conducted by GlaxoSmithKline and AstraZeneca, who, respectively, manufacture Advair Diskus and Symbicort. They were mandated by the FDA.

Results from both trials have been sent to the FDA for review and could lead to the lifting of the “black box” warning.

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Was This Article Helpful?

Show Comments (0)
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x